{"id":50990,"date":"2025-12-16T22:28:12","date_gmt":"2025-12-16T14:28:12","guid":{"rendered":"https:\/\/flcube.com\/?p=50990"},"modified":"2025-12-16T22:28:13","modified_gmt":"2025-12-16T14:28:13","slug":"sanofis-tolebrutinib-fails-phase-3-ppms-endpoint-halting-registration-plans","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50990","title":{"rendered":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that the Phase\u202f3 <strong>PERSEUS study<\/strong> (NCT04458051) of <strong>tolebrutinib<\/strong> in <strong>primary progressive multiple sclerosis (PPMS)<\/strong> did not meet its primary endpoint of delaying <strong>6\u2011month composite confirmed disability progression (cCDP)<\/strong>. Based on these results, Sanofi will <strong>not pursue regulatory registration<\/strong> for PPMS, representing roughly <strong>10% of the MS patient population<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-summary\">Regulatory &amp; Clinical Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>PERSEUS (NCT04458051), Phase\u202f3<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Primary progressive multiple sclerosis (PPMS)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Time to 6\u2011month cCDP<\/td><\/tr><tr><td><strong>Outcome<\/strong><\/td><td><strong>Not met<\/strong><\/td><\/tr><tr><td><strong>Decision<\/strong><\/td><td>Sanofi will not file for PPMS indication<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Oral, brain\u2011penetrant BTK inhibitor targeting neuroinflammation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Tolebrutinib<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>BTK inhibitor; crosses blood\u2011brain barrier<\/td><td>Targets CNS B\u2011lymphocytes and microglia<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Non\u2011relapsing secondary progressive MS (UAE provisional approval, July\u202f2025)<\/td><td>Under EU review; FDA Breakthrough Designation (Dec\u202f2024)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First BTK inhibitor designed for <strong>covert neuroinflammation<\/strong><\/td><td>Differs from peripheral\u2011acting MS therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PPMS Market:<\/strong> ~10% of <strong>2.8 million global MS patients<\/strong> = <strong>280,000 eligible patients<\/strong>; limited treatment options (only ocrelizumab approved)<\/li>\n\n\n\n<li><strong>Tolebrutinib Opportunity:<\/strong> Peak sales potential <strong>$1.5\u20112.0\u202fbillion<\/strong> in PPMS (if approved); failure removes <strong>~15%<\/strong> of total MS market opportunity<\/li>\n\n\n\n<li><strong>Remaining Indications:<\/strong> Non\u2011relapsing secondary progressive MS (nrSPMS) and other progressive forms remain under review; UAE approval validates <strong>regional pathway<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Sanofi:<\/strong> <strong>PPMS failure<\/strong> is a setback but does not impact broader BTK pipeline; focuses resources on <strong>nrSPMS<\/strong> where Phase\u202f3 data is expected Q2\u202f2026; maintains <strong>innovation leadership<\/strong> in CNS\u2011penetrant BTK class.<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> PPMS patients lose a potential <strong>oral alternative<\/strong> to ocrelizumab; ongoing nrSPMS trials may still address <strong>disability accumulation independent of relapse activity<\/strong>.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Highlights <strong>PPMS trial risk<\/strong>; BTK inhibitors face <strong>high placebo\u2011controlled disability progression rates<\/strong>; competitor <strong>Merck\u2019s evobrutinib<\/strong> also failed PPMS endpoint, suggesting <strong>class challenge<\/strong> in this indication.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding tolebrutinib\u2019s remaining indications, regulatory review timelines, and market projections. Actual results may differ due to clinical risks, regulatory feedback, or competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,867,24,147],"class_list":["post-50990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50990\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50990\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-16T14:28:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T14:28:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans\",\"datePublished\":\"2025-12-16T14:28:12+00:00\",\"dateModified\":\"2025-12-16T14:28:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990\"},\"wordCount\":330,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1606.webp\",\"keywords\":[\"Clinical trial results\",\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50990#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50990\",\"name\":\"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1606.webp\",\"datePublished\":\"2025-12-16T14:28:12+00:00\",\"dateModified\":\"2025-12-16T14:28:13+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50990\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50990#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50990","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans","og_description":"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.","og_url":"https:\/\/flcube.com\/?p=50990","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-16T14:28:12+00:00","article_modified_time":"2025-12-16T14:28:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50990#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50990"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans","datePublished":"2025-12-16T14:28:12+00:00","dateModified":"2025-12-16T14:28:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50990"},"wordCount":330,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","keywords":["Clinical trial results","NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50990#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50990","url":"https:\/\/flcube.com\/?p=50990","name":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50990#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","datePublished":"2025-12-16T14:28:12+00:00","dateModified":"2025-12-16T14:28:13+00:00","description":"Sanofi (NASDAQ: SNY) announced that the Phase\u202f3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint of delaying 6\u2011month composite confirmed disability progression (cCDP). Based on these results, Sanofi will not pursue regulatory registration for PPMS, representing roughly 10% of the MS patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50990#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50990"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50990#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","width":1080,"height":608,"caption":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50990#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50990"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50990\/revisions"}],"predecessor-version":[{"id":50992,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50990\/revisions\/50992"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50991"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}